Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...
I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...
Investor's Business Daily on MSN3h
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug FailsBristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
New York, New York-- (Newsfile Corp. - November 11, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated ...
ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday ...
By 2033, the market is expected to soar to US$ 67,200.1 million, reflecting the increasing reliance on auto-injectors for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback